Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Drug ‘Osimertinib’ provides new hope to lung cancer patients

PTI
Updated: June 8th, 2023, 07:20 IST
in International, Sci-Tech
0
Drug
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

New Delhi: A once-daily pill halved people’s risk of dying from a common lung cancer when they took the drug after tumour-removal surgery, trial results from a global study has proved. The research has been published recently in ‘The New England Journal of Medicine’. It states that taking the drug ‘Osimertinib’ after surgery dramatically reduced the risk of patients dying by 51 per cent.

The researchers randomly assigned eligible patients in a 1:1 ratio to receive Osimertinib (80mg once daily) or placebo until disease recurrence was observed. Of 682 patients who underwent randomisation, 339 received ‘Osimertinib’ also known as ‘Tagrisso’ and made by AstraZeneca, and 343 received placebo.

Also Read

Shubhanshu Shukla,

Shukla’s Axiom‑4 capsule to splash down July 15; India awaits safe return

3 hours ago
Claudia Sheinbaum elected first woman President of Mexico

Mexico calls US tariff hike unjust, seeks resolution through direct negotiations

3 hours ago

In the primary analysis population, an estimated 85 per cent of patients treated with Osimertinib were alive at five years compared to 73 per cent on placebo, the researchers said. In the overall trial population, an estimated 88 per cent of patients treated with ‘Osimertinib’ were alive at five years compared to 78 per cent on placebo, they said.

The study found that ‘Osimertinib’ reduced the risk of death by 51 per cent compared to placebo in both the primary analysis population, the researchers said.

“These highly anticipated overall survival results, with 88 per cent of patients alive at five years, are a momentous achievement in the treatment of early-stage EGFR-mutated lung cancer,” said principal investigator in the trial, Roy S Herbst, Deputy Director and Chief of Medical Oncology at Yale Cancer Centre and Smilow Cancer Hospital, US. “These data underscore that adjuvant treatment with ‘Osimertinib’ provides patients with the best chance of long-term survival,” Herbst said.

Susan Galbraith, executive vice-president, Oncology R&D, AstraZeneca, said ‘Osimertinib’ cut the risk of death by more than half in the adjuvant setting, further establishing this transformative medicine as the backbone treatment for epidermal growth factor receptor (EGFR)-mutated lung cancer.

“These results emphasise the importance of diagnosing patients with lung cancer early, testing for EGFR mutations and treating all those with an EGFR mutation with Tagrisso (Osimertinib),” Galbraith said.

The trial results were presented Monday during the Plenary Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago

 

Tags: AstraZenecacancerdeathdruglungOsimertinib
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Arya Ayushman

December 12, 2019
#MyPaperBagChallenge

Rajashree Pravati Mohanty

December 12, 2019
#MyPaperBagChallenge

Parbati Mohanty

December 12, 2019
#MyPaperBagChallenge

Jyotshna Mayee Pattnaik

December 12, 2019
#MyPaperBagChallenge

Shreyanshu Bal

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Spinoj Pattnaik

December 12, 2019
#MyPaperBagChallenge

Geetanjali Patro

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Bijswajit Pradhan

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Mrutyunjaya Behera

December 12, 2019
#MyPaperBagChallenge

Anshuman Sahoo

December 12, 2019
#MyPaperBagChallenge

Aman Kumar Barisal

December 12, 2019
#MyPaperBagChallenge

Akshaya Kumar Dash

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Surya Sidhant Rath

December 12, 2019
#MyPaperBagChallenge

Sitakanta Mohanty

December 12, 2019
#MyPaperBagChallenge

Manas Samanta

December 12, 2019
#MyPaperBagChallenge

Pratyasharani Ghibela

December 12, 2019
#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Jhili Jena

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar

December 12, 2019
#MyPaperBagChallenge

Akriti Negi

December 12, 2019
#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar Ghibela

December 12, 2019

Archives

Editorial

Socialist Democrat

Aakar Patel
July 13, 2025

One of the most remarkable democratic developments of recent times came from New York City this month. A 33-year-old man...

Read more

Tripura’s IAS Exodus

July 12, 2025

It’s hard not to see the flight of over a dozen IAS officers from Tripura’s cadre as a crypto-threshold moment....

Read more

Toll Sucks Life

Nitin Gadkari
July 9, 2025

Union Road Transport and Highways Minister Nitin Gadkari took everyone by surprise when at a function in Nagpur, where the...

Read more

Bloodline

BJP-Shiv Sena
July 8, 2025

The coming together of the Thackeray cousins – Raj Thackeray, chief of the Maharashtra Navnirman Sena (MNS) and Shiv Sena...

Read more
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2024 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2024 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2024 All rights Reserved by OrissaPOST